A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy

Abstract

Patients with chronic lymphocytic leukemia (CLL) who receive chemoimmunotherapy and do not achieve complete remission experience significantly shortened progression-free interval (PFS). Additionally, the majority of patients treated for relapsed disease demonstrate evidence of measurable disease. Eradication of minimal residual disease (MRD) results in improved PFS and overall survival. Maintenance therapy might result in eradication of MRD and improve response duration but might be associated with an increase in incidence of infectious complications. Flavopiridol is a broad cyclin-dependent kinase (CDK) inhibitor with established safety and efficacy in patients with relapsed CLL, particularly patients with high-risk cytogenetic features. A pharmacologically derived schedule was utilized as consolidation therapy in this phase I study to assess the safety and feasibility of outpatient therapy with flavopiridol in patients with low tumor burden. Flavopiridol was administered as a 30-min loading dose of 30 mg/m2 followed by a 4-h infusion of 30 mg/ m2 once weekly for 3 weeks every 5 weeks (1 cycle) for planned 2 cycles in ten patients. Therapy was extremely well tolerated and no patient developed acute tumor lysis syndrome. The most common toxicities were gastrointestinal. Of the patients, 22 % improved their response from a PR to CR. Eighty-eight percent experienced a reduction in tumor burden as measured by extent of bone marrow involvement including patients with del17p and complex karyotype. The study establishes the safety and efficacy of flavopiridol as consolidation therapy after chemoimmunotherapy for patients with CLL. Further evaluation is required in larger trials for the utility of CDK inhibitors as consolidation or maintenance strategies. Registration number at ClinicalTrials.gov: NCT00377104.

Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV

“…The Smac mimetic, Birinapant is undergoing clinical evaluation to treat refractory haematological and solid tumours, including lymphoma (Amaravadi et al, 2015) and epithelial ovarian cancer (Noonan et al, 2016). Flavopiridol decreases XIAP and is under investigation for the treatment of chronic lymphocytic leukemia (Awan et al, 2016; Blachly et al, 2016). The impact of these inhibitors on uninfected cells also requires careful investigation to minimise undesirable toxicities on uninfected cells.…”

Therapeutic Potential of Flavonoids in Pain and Inflammation: Mechanisms of Action, Pre-Clinical and Clinical Data, and Pharmaceutical Development

“…Alvocidib, or Flavopiridol (Tolero Pharmaceuticals, Inc.) is a synthetic analog of a naturally occurring flavone extracted from Dysoxylum binectariferum. It has a CDK9 kinase inhibitor activity, arresting cell cycle at G1 phase, and, therefore, has been shown as a promising therapy for patients with acute myeloid leukemia and chronic lymphocytic leukemia [206,251]. Enzogenol ® , a flavonoid-rich extract of Pinus radiate containing approximately 80% total proanthocyanidins and other water-soluble flavonoids, has been linked to neuroprotection properties [252,253] and beneficial vascular effects [254].…”

Sotetsuflavone Induces Autophagy in Non-Small Cell Lung Cancer Through Blocking PI3K/Akt/mTOR Signaling Pathway in Vivo and in Vitro

“…In vivo studies have shown that flavonoids were able to inhibit carcinogenesis, and the effect was mainly characterized as being related to molecular events during the stages of initiation, promotion, and progression (Zhao et al, 2017). Clinical trials that have examined the use of flavonoids have been conducted with the goal of achieving cancer prevention or in order to obtain better therapeutic effect (Awan et al, 2016;Zhang et al, 2018a). Therefore, flavonoids can and should be further developed as potentially promising compounds for chemoprevention and chemotherapy of cancer (Zhang et al, 2018a).…”